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============

Chronic pain is characterized by enhanced responses to different external stimuli, also known as hyperalgesia, and is induced by inflammation following injury ([@B20]). When damage or inflammation occurs, mediators such as prostaglandins, cytokines, chemokines, neuropeptides, and nerve growth factor (NGF), are released ([@B53]). These mediators maintain pain signaling that starts in the periphery and results in both peripheral and central sensitization, ultimately contributing to chronic pain. From the tremendous efforts of researchers in the fields of neurology and signaling, we have a deeper understanding of the mechanisms that drive pain. Additionally, chronic pain from a variety of sources, including injuries and disease, has promoted the development of targeted therapies ([@B29]; [@B4]; [@B36]; [@B12]).

Current methods of pain relief and enhanced quality of life predominantly rely on surgery ([@B8]), medication ([@B47]), physical therapy ([@B1]), and psychological therapy ([@B7]). The use of medications, including opioid drugs ([@B41]; [@B2]) and non-opioid drugs ([@B22]), has increased significantly over the last several decades. Extensive use of medication has been associated with severe side effects, including drug addiction ([@B34]), tolerance ([@B54]), abuse ([@B49]; [@B48]), and even death. These significant drawbacks of clinically available drugs have shifted the focus of drug development on improving the targeting of drugs, reducing side effects, and prolonging the release of the active compounds ([@B13]). However, due to their rapid metabolism, these current formulations are challenging to manufacture reproducibly, and the required dosing can cause poorly tolerated physical side effects.

The integration of pharmacological sciences with nanotechnology has been a key step toward creating more effective drugs for chronic pain with fewer negative implications ([@B11]). With the advent of nanotechnology, the field of drug delivery has undergone extensive development resulting in several nanomaterials being approved for clinical use ([@B46]). Compared with traditional formulations, nanomaterials can be efficiently loaded with drugs ([@B10]), protect the stability of protein-based drugs ([@B51]), sustain controlled release with prolonged circulation time ([@B5]), and are also designed to be highly biocompatible ([@B30]). In the field of chronic pain relief, nanomaterials have been developed explicitly for the targeted delivery and release of pain medication. Inspired by the first Food and Drug Administration (FDA)-approved nanodrug Doxil ([@B3]), nanotechnology is being applied to many biomedical applications, but with a limited focus on chronic pain relief. In this minireview, we cover the development of medications for chronic pain relief that employ nanotechnology, including targeted and non-targeted nanomaterials, and provide perspective for future applications of nanotechnology in pain relief ([Figure 1](#F1){ref-type="fig"}).

![Current main strategies on chronic pain relief using nanotechnology including the delivery of drugs using nanocarriers, active targeting nanocarriers and ROS clearance via nanomaterials.](fbioe-08-00682-g001){#F1}

Non-Targeted Nanomaterials for Pain Relief {#S2}
==========================================

Nanomaterials can be designated as organic, inorganic, and metal-organic nanomaterials based on their components. All three categories of nanomaterials have been used as controlled release delivery systems to minimize side effects and promote treatment efficacy for pain medication. Nanomaterials can be used to encapsulate both free molecules and protein-based drugs to increase blood circulation time with sustained, controlled release, resulting in long-lasting pain relief with minimal side effects. In this section, we will present the development of organic and inorganic non-targeted nanomaterials, which have been broadly applied to several pain relief drugs.

When introducing nanomaterials into a clinical application, a major preliminary concern is the biocompatibility of the proposed nanomaterial. Consequently, nanomaterials that have already been approved by the FDA are generally the first to be considered by researchers. FDA approved nanomaterials are mainly organic in nature such as liposomes ([@B23]), PLGA ([@B27]), and other carbon based polymer nanomaterials ([@B31]). Several inorganic nanomaterials have also been approved, but remain in the minority ([@B44]).

Liposomes are especially attractive since they are derived from cellular-like lipids, making them extremely biocompatible, and are relatively well studied. A number of liposome formulations have been the focus of emerging clinical trials. For example, PEGylated-liposomes have been used to encapsulate and enhance the accumulation of zoledronic acid (ZOL), an inhibitor of the ras-dependent Erk-mediated pathway, for the treatment of neuropathic pain ([@B6]). Caraglia et al. proved that this liposomal based delivery system passed across the blood brain barrier (BBB), promoting its ability to release ZOL for efficient pain mitigation. Likewise, [@B39] encapsulated the drug hydromorphone using the liposomes and tested its neuropathic pain relief ability in rats. As expected, liposomal delivery enabled prolonged pain relief with only a single injection.

Although liposomes have many advantages and benefit from established synthesis procedures, the next generation of nanomaterials is focused on a myriad of tunable features including size, surface properties, responsiveness, controlled circulation time, high loading efficiency, and the ability to target specific tissues. [@B9] compared PEG-modified lipid nanomaterials to chitosan-modified lipid nanomaterials and PLGA nanomaterials for their ability to deliver cannabinoids via oral administration. The three biocompatible nanomaterials varied in their performance, providing design criteria for the development of nanomaterials for pain relief drug delivery.

The overproduction of reactive oxygen species (ROS) at sites of inflammation can result in chronic pain; consequently, nanomaterials that consume ROS are a promising avenue for pain relief ([@B17]). Along these lines, [@B25] employed fullerol nanomaterials, which are known to consume ROS, to protect inflammatory sites and relieve the pain.

Integrating an FDA-approved nanomaterial PLGA with bupivacaine, [@B14] studied its drug release mechanism and ability to relieve pain. Likewise, [@B37] synthesized a new combination of nanomaterial, naocurcumin, composed of PLGA and curcumin to attenuate morphine tolerance. Naocurcumin was orally administrated to mice revealing excellent biocompatibility and ability to mitigate tolerance to morphine. Apart from small molecule drug delivery, biomedicine and nanotechnology have also been focused on the delivery of biomolecules such as Ribonucleic Acid (RNA). Based on the ability of p38 small interfering RNA (p38 siRNA) to assuage neuropathic pain, [@B38] used PLGA nanomaterials to encapsulate the p38 siRNA enhancing its stability and slow release for pain alleviation.

In addition to organic nanomaterials, inorganic nanomaterials have also been designed and applied to address chronic pain. Compared with their organic counterparts, inorganic nanomaterials are generally more stable, ensuring prolonged circulation, and can be designed to have more physicochemical properties, such as controlled drug release via stimulation by an external field. Recently, [@B40] published on a graphene oxide (GO) based nano-system for neuropathic pain relief. Specifically, these GO nanomaterials provided a large surface area to load lidocaine and thalidomide, enhancing the capacity of these drugs to relieve neuropathic pain. In a separate study of inorganic nanomaterials, [@B50] demonstrated that ultra-small magnetic iron oxide particles exhibited dose-dependent analgesic effects for the treatment of chronic pain. Using hydroxyapatite nanomaterials, which are biocompatible and have been approved for use in bone-related diseases, [@B16] encapsulated and efficiently delivered NR2B-siRNA into mice via intrathecal injection. These nanoparticles exhibited statistical levels of pain mitigation that motivate the future development of materials for siRNA delivery.

Targeted Nanomaterials for Pain Relief {#S3}
======================================

Despite the advantages of using nanomaterials to encapsulate drugs for the alleviation of chronic pain, their limited treatment efficacy has drawn attention to the critical need to develop more promising solutions. Since the causes of chronic pain are variable, the requirements for drug type and dosing differ depending on the treatment intervention. Enhancing the concentration of the drug at the indented site of action is one way to increase the efficacy of the treatment and minimize off target effects. Modification of nanomaterials using targeting substances such as peptides and antibodies can help achieve this site-specific targeting. Additionally, the route of administration is a critical consideration for the use of these targeted materials in their corresponding chronic pain models. For example, exposed sites of chronic pain on the skin can be topically treated using a smear or spray, whereas an injection through the dorsal root ganglion is more suitable for chronic spinal nerve pain. Internal injury or disease may benefit from oral, intranasal, intramuscular, or intravenous injections, depending on the source and location of the pain. In the following section, we will highlight research focused on targeted strategies to promote efficient chronic pain treatment.

Surface modification of nanomaterials is a simple yet effective way to enhance the location-specific absorption of delivered drugs. For example, [@B18] synthesized opioid fentanyl-encapsulated liposomes with integrin targeting motifs, revealing increased stability, enhanced analgesic ability, and reduced plasma drug exposure after aerosol administration. Likewise, [@B43] designed polyester-based nanoparticles consisting of PLGA and glycosylated heptapeptides for the delivery of the opioid agonist loperamide. Excitingly, these nanoparticles not only crossed the BBB via peptide targeting but also exhibited sustained release of loperamide. [@B24] modified PLGA nanomaterials with lactoferrin and transferrin as the ligands, ensuring brain targeting for better pain relief. Additionally, [@B33] showed enhanced tizanidine HCl delivery to the brain using surface-modified thiolated chitosan nanomaterials when they were administered intranasally.

Pain evoked by cancer, as well as some cancer medications, has drawn substantial attention from researchers studying pain relief. To address cancer-induced bone pain, [@B15] modified PLGA with the bone microenvironment targeting amino-bisphosphonate, to deliver cabazitaxel for efficient pain relief in a bone metastatic prostate cancer model. To mimic the endogenous response in inflammatory sites, Hua et al. designed opioid loaded liposomes with the capacity to target inflammatory environments and release the corresponding drugs for simultaneous pain relief ([@B19]). Important research described by [@B35] reveals that their novel pH-responsive nanomaterials with the ability to target neurokinin-1 receptors (NK~1~R) in the endosome display excellent capacity for preventing chronic pain. The accumulation of these pH-responsive nanomaterials in NK~1~R-containing endosomes resulted in sustained chronic pain relief. To date, targeted nanomaterial design is mostly focused on modification with targeting ligands, but other strategies for active targeting remain largely unexplored, which will be presented in the perspective section.

Discussion and Perspective {#S4}
==========================

The urgent demand for chronic pain relief has highlighted the need for advancements in nanotechnology and pharmaceutical science, attracting attention from scientists in materials science, biomaterials, and chemistry. After decades of progress, the use of nanotechnology for chronic pain relief has been regarded as promising, prompting several clinical trials. However, the development of these smart nanomaterials is still in its infancy, with many unexplored opportunities. This minireview aims to highlight current difficulties in the pharmaceutical field and the advantages of applying nanotechnology to address these shortcomings. Herein, we have detailed some representative examples of organic and inorganic nanomaterials that facilitate controlled release, passive and active targeting, and the utilization of external energy fields. Based on these previous studies, we would like to provide some perspective thoughts on nanomaterial design for chronic pain relief ([Figure 2](#F2){ref-type="fig"}):

![Future outlooks that can be taken up by using nanotechnology for chronic pain relief.](fbioe-08-00682-g002){#F2}

1.  Oral administration of drugs poses a series of biological barriers requiring enhanced stability in the stomach, followed by the ability to be absorbed and be effective. Therefore, careful consideration of size, surface charge, and whether to modify the targeted ligands are necessary when designing a nanomaterial for this application. Moreover, non-conventional nanomaterials such as exosomes, cell membrane-derived vesicles ([@B45]) which have the targeting ability could also be investigated for oral drug delivery.

2.  Since each drug has its own kinetic profile, it is necessary to design appropriate nanomaterials to achieve a balance between drug release rate and drug action time. Additionally, combining interfering RNA with nanotechnology may prove to be an important strategy for pain mitigation.

3.  To improve therapeutic effects while minimizing side effects, a balance between the drug load and the release rate needs to be achieved. Similarly, improving the targeting efficiency of nanocarriers will reduce off-target effects by minimizing exposure to non-targeted organs during circulation.

4.  The phenomenon of protein coronas ([@B26]) has been attributed to the low efficacy of targeted nanomaterials, as serum proteins bind to the surface resulting in masking of the targeting epitopes and rapid clearance by phagocytic cells. Avoiding the formation of protein coronas is a critical avenue of research for the advancement of all nanomaterials for drug delivery. One proven method to mitigate corona formation is to modify the surface of nanomaterials with PEG.

5.  In pharmacology, the rapid development of multi-target drugs ([@B28]) has greatly improved the therapeutic outcome of chronic pain. Integrating nanotechnology with these enhanced formulations could allow for multi-drug co-delivery or their targeted release multiple sites. These methods have the capability to significantly reduce side effects, improve therapeutic outcomes, and reduce drug tolerization.

6.  Although nanomaterials have experienced rapid developmental growth over the past few decades, there is an urgency to ensure the safety of these materials and establish a unified evaluation standard.

7.  Although theranostic is a popular concept in the field of cancer, treatments for chronic pain treatment lack an intuitive imaging modality to monitor treatment progression and directly visualize therapeutic effects. Luminescent nanomaterials ([@B32]) could be introduced into the field to achieve the integration of diagnosis and treatment, similar to their use in cancer therapeutics.

8.  The energy-conversion properties of inorganic nanomaterials can be employed to treat chronic pain, such as generating electrical signals when stimulated by light, ([@B42]) subsequently activating or inhibiting ion channels from playing an analgesic role. Additionally, magnetic nanomaterials ([@B52]) can also use external magnetic fields to achieve targeted magnetic therapy.
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9.  Microneedles ([@B21]) can be applied to the field of analgesia, where nanomaterials are integrated into the front end of the device to greatly reduce the pain caused by injecting drugs to patients.

10. Inhalation of apposite nanomaterials that encapsulate drugs could be leveraged for chronic pain relief, especially lung-related pain.

As a collaboration between many fields of study, we believe that the application of nanotechnology to address chronic pain has a bright future. We hope that this field will develop steadily, with clinical relevance, to improve the quality of life for patients with chronic pain.
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